Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (Symbol: LTRN) is at the forefront of innovation in the realm of cancer treatment, striving to deliver the most effective therapies to patients who are poised to benefit the most. The company employs a pioneering precision medicine approach to cancer treatment, leveraging biomarker-based genetic screening to identify and treat patients who would derive the greatest benefit from their drugs. This method not only reduces the cost of drug development but also expedites the time to market.
Lantern Pharma's core business revolves around its proprietary artificial intelligence (AI) and machine learning (ML) platform, RADR. The RADR platform assimilates oncology-focused data points and utilizes advanced ML algorithms to address complex, billion-dollar challenges in cancer drug development. This innovative platform has significantly accelerated the company's growing pipeline of precision therapies, with input from world-class scientific advisors and collaborators.
In addition to its in-house development, Lantern Pharma adopts a strategic approach by acquiring or partnering with promising drug and diagnostic companies. This strategy is aimed at advancing personalized medicine programs for cancer patients, thus broadening the company's impact in the oncology space.
With a commitment to transforming the cost, pace, and timeline of oncology drug discovery and development, Lantern Pharma continues to make strides in the development of precision therapies. The company's recent achievements and ongoing projects underscore its potential to revolutionize cancer treatment and deliver significant value to both patients and stakeholders.
Lantern Pharma Inc. (NASDAQ: LTRN) reported financial results for Q3 2020, highlighting significant advancements in oncology drug development and its proprietary AI platform, RADR®. The company has three compounds in development: LP-100 in Phase 2 for metastatic prostate cancer, LP-300 preparing for Phase 2 for non-small cell lung cancer, and LP-184 in preclinical stages for various cancers. Notably, RADR® surpassed one billion data points, enhancing the drug development process. Cash and equivalents stood at $20.8 million, marking a substantial rise from $1.2 million at 2019's end, while net losses increased to $1.7 million.
Lantern Pharma (LTRN) will host a conference call on October 29, 2020, at 4:00 p.m. ET to discuss its financial and operating results for the third quarter ending September 30, 2020. The call, led by CEO Panna Sharma, will be accessible via teleconference and online, with a replay available until November 29, 2020. Lantern Pharma focuses on drug discovery and development in oncology, utilizing its RADR® artificial intelligence platform to optimize therapeutic outcomes for patients.
Lantern Pharma (NASDAQ: LTRN) announced an enhanced collaboration with Georgetown University focusing on LP-184, a small molecule drug candidate for targeted treatment of certain solid tumors like prostate and pancreatic cancers. The initial phase yielded strong evidence of LP-184's efficacy, particularly in prostate cancer cells expressing PTGR1. Next steps involve expanding research to validate LP-184's mechanism of action and confirming genomic data which could lead to more personalized treatments. Lantern aims to streamline drug development costs using its RADR® AI platform.
Lantern Pharma (LTRN) has announced a collaboration with Fox Chase Cancer Center to advance the development of LP-184 for pancreatic cancer. The partnership aims to create a robust gene signature to enhance the efficacy of targeted therapies. CEO Panna Sharma emphasized the importance of collaborations in leveraging their RADR® A.I. platform for drug development. This agreement could streamline the path to clinical trials, potentially reducing costs and improving patient outcomes in a field where survival rates remain low. LP-184 is a next-generation alkylating agent currently in preclinical development.
Lantern Pharma (LTRN), a clinical-stage biopharmaceutical company, announced upcoming investor presentations for September 2020. CEO Panna Sharma will participate in several conferences, including the LD Micro 500 on September 1 at 2:40 p.m. ET, and the H.C. Wainwright Global Investor Conference on September 15 at 4:30 p.m. ET. The company utilizes its proprietary RADR® A.I. platform for oncology drug development, focusing on precision therapeutics. Interested investors can reach out for meetings through the provided contact information.
Lantern Pharma (LTRN), a clinical-stage biotechnology company, announced an upcoming interview with CEO Panna Sharma on The RedChip Money Report, airing on Bloomberg International on August 16, 2020, at 6 p.m. local time. The interview will cover the company’s A.I.-based drug discovery platform and ongoing clinical trials. Viewers can also access the segment on the Action Channel in the U.S. at 11 a.m. ET on the same day. Lantern Pharma focuses on using machine learning and genomics to develop targeted oncology drugs.
Lantern Pharma (NASDAQ: LTRN) announced its Q2 2020 financial results and updates on its R&D pipeline. The company reported a cash position of $23.8 million as of June 30, 2020, due to a successful IPO that raised $26.3 million. R&D expenses decreased to $157,023, while G&A expenses rose to $676,399 due to public company transition costs. The net loss was $833,422, up from $629,393 in Q2 2019. Key highlights include advancements in manufacturing capabilities, the RADR® platform exceeding 500 million data points, and ongoing clinical trials for LP-300 and LP-184.
Lantern Pharma (LTRN) will host a conference call on July 30, 2020, at 8:00 a.m. ET to discuss its financial and operational results for Q2 2020, ending June 30, 2020. Panna Sharma, the company's CEO, will lead the call alongside the management team. The call can be accessed via teleconference or online. A replay will be available for 30 days post-call. Lantern Pharma focuses on oncology therapeutics using its RADR® AI platform, aiming to improve patient outcomes through precision medicine by identifying suitable patient populations for its drug candidates.
Lantern Pharma (NASDAQ: LTRN) has entered agreements with top contract manufacturers to develop and produce oncology drugs LP-300 and LP-184. LP-300 targets non-small cell lung cancer in never-smokers and is approaching Phase 2 trials, with a significant market potential. Meanwhile, LP-184, aimed at genomically defined tumors, is set for Phase 1 trials in late 2021 or early 2022. The company leverages its RADR® A.I. platform, containing nearly 500 million data points, to enhance drug development and identify effective patient populations for its therapies.
Lantern Pharma (NASDAQ: LTRN) announced it has surpassed 450 million curated data points in its RADR® platform, aimed at enhancing personalized cancer therapies. This milestone supports the identification of specific drug responses in cancer patients and enables collaboration with partners to develop faster algorithms. Lantern's focus is on non-small cell lung cancer, ovarian cancer, and glioblastoma, improving outcomes and reducing costs. The company is on track to exceed 1 billion data points, significantly advancing its pipeline and drug development capabilities.
FAQ
What is the current stock price of Lantern Pharma (LTRN)?
What is the market cap of Lantern Pharma (LTRN)?
What does Lantern Pharma Inc. specialize in?
What is the RADR platform?
How does Lantern Pharma's approach reduce drug development costs?
What is the company's strategy for growth?
How does Lantern Pharma use AI in drug development?
Who are the key collaborators with Lantern Pharma?
What are some of Lantern Pharma's recent achievements?
Why is precision medicine important in cancer treatment?
How does Lantern Pharma's strategy benefit cancer patients?
What is the significance of biomarker-based genetic screening?
